Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

Journal Articles

Leukapheresis for acute leukemia with hyperleukocytosis: Line complications, resource utilization, and early mortality outcomes

Elizabeth Pollard, Brigitte Jia, Jarrod Smith, Somedeb Ball, Ashwin Kishtagari, Sanjay Mohan, Kateryna Fedorov, Vivek Patel

Blood (2025) 146 (Supplement 1): 5188.

https://doi.org/10.1182/blood-2025-5188

Published: 2025

Journal Articles

Genomic and phenotypic impact of FHD-286–induced inhibition of SMARCA4/2 in patients with relapsed/refractory myeloid malignancies

Mike Collins, David Lahr, Eytan Stein, Courtney DiNardo, Ashwin Kishtagari, Brian Ball, Kim Horrigan, Alexis Khalil, Katie D'Aco, Mia Bosinger, Salih Topal, Nicholas Spidale, Alfonso Quintas-Cardama, Gromoslaw Smolen

Blood (2025) 146 (Supplement 1): 655.

https://doi.org/10.1182/blood-2025-655

Published: 2025

Journal Articles

The impact of clonal hematopoiesis on CAR-T cell therapy outcomes: A single-center analysis

Grace Mercadante, Joseph Van Amburg, Yash Pershad, Naimisha Marneni, Jamye O'Neal, Emily F. Mason, Shakthi Bhaskar, Eden Biltibo, Vivek Patel, Reena Jayani-Kosarzycki, Bhagirathbhai Dholaria, Adetola Kassim, Michael Savona, Olalekan Oluwole, Andrew Jallouk, Alexander Bick, Ashwin Kishtagari

Blood (2025) 146 (Supplement 1): 4158.

https://doi.org/10.1182/blood-2025-4158

Published: 2025

Journal Articles

Pacritinib in patients with high-risk myelofibrosis: Outcomes from post-hoc analyses of two Phase 3 studies

Pankit Vachhani, Nikolai Podoltsev, Ashwin Kishtagari, Purvi Suthar, Michael Vredenburg, Karisse Roman-Torres, Aaron Gerds

Blood (2025) 146 (Supplement 1): 2019.

https://doi.org/10.1182/blood-2025-2019

Published: 2025

Journal Articles

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Blood (2025) 146 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2025-2018

Published: 2025

Journal Articles

Impact of RAS mutations on outcomes in newly diagnosed AML patients

Melanie Naranjo, Jamila Mammadova, Sarah Profitt, Bradley Yelvington, Callee Brooks, Kathryn Kennedy, Erica Mittlebeeler, Ashwin Kishtagari, Somedeb Ball, Sanjay Mohan, Michael Savona, Kateryna Fedorov

Blood (2025) 146 (Supplement 1): 7026.

https://doi.org/10.1182/blood-2025-7026

Published: 2025

Journal Articles

Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes

Blood (2025) 146 (Supplement 1): 239.

https://doi.org/10.1182/blood-2025-239

Published: 2025

Journal Articles

Behind the blood-brain barrier: Contemporary screening practice patterns and trends of central nervous system involvement in acute myeloid leukemia treated with intensive regimens and hypomethylating agent/venetoclax

Jamila Mammadova, Melanie Naranjo, Sarah Profitt, Bradley Yelvington, Callee Brooks, Kian Rahbari, Kathryn Kennedy, Erica Mittlebeeler, Somedeb Ball, Michael Savona, Ashwin Kishtagari, Sanjay Mohan, Kateryna Fedorov

Blood (2025) 146 (Supplement 1): 1621.

https://doi.org/10.1182/blood-2025-1621

Published: 2025

Journal Articles

An independent, multi-center analysis of the post-approval utilization and efficacy of pacritinib and momelotinib in patients with myelofibrosis

Andrew Kuykendall, Douglas Tremblay, Anthony Hunter, Pankit Vachhani, Alexander Coltoff, Anand Patel, Ashwin Kishtagari, Jeremy DiGennaro, Dahniel Sastow, Sandra Jones, Jay Jarodiya, Georgio Medawar, Shiv Shah, Naimisha Marneni, Megan Metzger, Ashley Yu, Rami Komrokji, John Mascarenhas

Blood (2025) 146 (Supplement 1): 5600.

https://doi.org/10.1182/blood-2025-5600

Published: 2025

Journal Articles

Oral decitabine-cedazuridine versus parenteral hypomethylating agents in treatment-Naïve TP53-mutated Myelodysplastic Syndromes

Parth Patel, Michael Canonico, Hayley Hawkins, Michael Zargari, Kathryn Kennedy, Katherine Walsh, Erica Mittlebeeler, Bradley Yelvington, Laura Lee, Emily F. Mason, Kateryna Fedorov, Ashwin Kishtagari, Sanjay Mohan, Michael Savona, Somedeb Ball

Blood (2025) 146 (Supplement 1): 7389.

https://doi.org/10.1182/blood-2025-7389

Published: 2025

Journal Articles

Addition of venetoclax to hypomethylating agent offers limited incremental benefit for patients with treatment-naïve TP53-mutated myelodysplastic syndromes

Michael Canonico, Parth Patel, Hayley Hawkins, Kateryna Fedorov, Katherine Walsh, Kathryn Kennedy, Erica Mittlebeeler, Sarah Profitt, Sanjay Mohan, Emily F. Mason, Ashwin Kishtagari, Michael Savona, Somedeb Ball

Blood (2025) 146 (Supplement 1): 7388.

https://doi.org/10.1182/blood-2025-7388

Published: 2025

Journal Articles

Impact of clonal hematopoiesis and BRAF mutation status on clinical outcomes in melanoma patients treated with immune checkpoint inhibitors

Mason Alford-Holloway, Joseph Van Amburg, Yash Pershad, Leo Luo, Michael Savona, Douglas Johnson, Alexander Bick, Ashwin Kishtagari

Blood (2025) 146 (Supplement 1): 7661.

https://doi.org/10.1182/blood-2025-7661

Published: 2025

Journal Articles

High remission rates with FLAG-ida-venetoclax in acute myeloid leukemia: “Less is More” on days of venetoclax in the intensive regimen

Kateryna Fedorov, Kathryn Kennedy, Erica Mittlebeeler, Sarah Profitt, Bradley Yelvington, Callee Brooks, Ashwin Kishtagari, Sanjay Mohan, Michael Savona, Somedeb Ball

Blood (2025) 146 (Supplement 1): 1666.

https://doi.org/10.1182/blood-2025-1666

Published: 2025

Journal Articles

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood (2024) 144 (19): 2033–2044.

https://doi.org/10.1182/blood.2024024756

Published: 2024

Includes: Supplemental data

Journal Articles

Bone Marrow Spatial Multi-Omics Identifies Reduced Interactions between Hematopoietic Stem Cells and Myeloid Cells in Myelodysplastic Syndrome

Alyssa C. Parker, Joseph C. Van Amburg, Tianzi Zhang, Diane C. Saunders, Thomas J. Gracie, Pawan Bhat, J. Brett Heimlich, John W. Hickey, Emily F. Mason, Ashwin Kishtagari, P. Brent Ferrell, Jr., Alexander G. Bick

Blood (2024) 144 (Supplement 1): 4577.

https://doi.org/10.1182/blood-2024-210307

Published: 2024

Journal Articles

Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis

Blood (2024) 144 (Supplement 1): 3206.

https://doi.org/10.1182/blood-2024-211623

Published: 2024

Journal Articles

Post-Approval Utilization of Pacritinib and Momelotinib in Patients with Myelofibrosis and Analysis of Early Treatment Outcomes

Jeremy V. DiGennaro, George Concepcion, Najla H. Al Ali, Onyee Chan, Alison R. Walker, Zhuoer Xie, Eric Padron, Jeffrey E Lancet, David Sallman, Ashwin Kishtagari, Pankit Vachhani, John O. Mascarenhas, Rami S. Komrokji, Andrew T. Kuykendall

Blood (2024) 144 (Supplement 1): 4561.

https://doi.org/10.1182/blood-2024-202579

Published: 2024

Journal Articles

Impact of Co-Mutations, Monocytic Differentiation, and Choice of Hypomethylating Agent Combined with Venetoclax on the Predictive Value of Molecular Prognostic Risk Signature in Newly Diagnosed AML Patients

Kateryna Fedorov, Somedeb Ball, James E Denney, Alexis R Froenlich, Ashwin Kishtagari, Sanjay Mohan, Michael R. Savona, Emily F. Mason

Blood (2024) 144 (Supplement 1): 1474.

https://doi.org/10.1182/blood-2024-194259

Published: 2024

Journal Articles

Combined Natural Language Processing and Gpt-4 Pathology Report Interpretation Efficiently Identify a Myelodysplastic Syndrome Cohort for Large Scale Clinical Research Applications

Thomas J. Gracie, Yash Pershad, Cosmin Bejan, Alexander G. Bick, Brent Ferrell, Ashwin Kishtagari

Blood (2024) 144 (Supplement 1): 3607.

https://doi.org/10.1182/blood-2024-201083

Published: 2024

Journal Articles

Selinexor-Driven Regulation of Proinflammatory Cytokines May Lead to Stabilization of Hematologic Parameters and Bone Marrow Function in Patients with Myelofibrosis: Case Study from the Phase 1 Sentry Trial

Haris Ali, Keri Maher, Ashwin Kishtagari, Sanjay R Mohan, Josef T. Prchal, Yi Chai, Christopher J. Walker, Trinayan Kashyap, Steve Kye, Srinivas K Tantravahi

Blood (2024) 144 (Supplement 1): 6676.

https://doi.org/10.1182/blood-2024-207778

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Leukapheresis for acute leukemia with hyperleukocytosis: Line complications, resource utilization, and early mortality outcomes

Genomic and phenotypic impact of FHD-286–induced inhibition of SMARCA4/2 in patients with relapsed/refractory myeloid malignancies

The impact of clonal hematopoiesis on CAR-T cell therapy outcomes: A single-center analysis

Pacritinib in patients with high-risk myelofibrosis: Outcomes from post-hoc analyses of two Phase 3 studies

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Impact of RAS mutations on outcomes in newly diagnosed AML patients

Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes

Behind the blood-brain barrier: Contemporary screening practice patterns and trends of central nervous system involvement in acute myeloid leukemia treated with intensive regimens and hypomethylating agent/venetoclax

An independent, multi-center analysis of the post-approval utilization and efficacy of pacritinib and momelotinib in patients with myelofibrosis

Oral decitabine-cedazuridine versus parenteral hypomethylating agents in treatment-Naïve TP53-mutated Myelodysplastic Syndromes

Addition of venetoclax to hypomethylating agent offers limited incremental benefit for patients with treatment-naïve TP53-mutated myelodysplastic syndromes

Impact of clonal hematopoiesis and BRAF mutation status on clinical outcomes in melanoma patients treated with immune checkpoint inhibitors

High remission rates with FLAG-ida-venetoclax in acute myeloid leukemia: “Less is More” on days of venetoclax in the intensive regimen

Risk prediction for clonal cytopenia: multicenter real-world evidence

Bone Marrow Spatial Multi-Omics Identifies Reduced Interactions between Hematopoietic Stem Cells and Myeloid Cells in Myelodysplastic Syndrome

Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis

Post-Approval Utilization of Pacritinib and Momelotinib in Patients with Myelofibrosis and Analysis of Early Treatment Outcomes

Impact of Co-Mutations, Monocytic Differentiation, and Choice of Hypomethylating Agent Combined with Venetoclax on the Predictive Value of Molecular Prognostic Risk Signature in Newly Diagnosed AML Patients

Combined Natural Language Processing and Gpt-4 Pathology Report Interpretation Efficiently Identify a Myelodysplastic Syndrome Cohort for Large Scale Clinical Research Applications

Selinexor-Driven Regulation of Proinflammatory Cytokines May Lead to Stabilization of Hematologic Parameters and Bone Marrow Function in Patients with Myelofibrosis: Case Study from the Phase 1 Sentry Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only